Full-Time

Regional Director Medical Science Liaison

Medical Science Liaison

Posted on 5/12/2026

Collegium Pharmaceutical

Collegium Pharmaceutical

501-1,000 employees

Specialty biopharmaceuticals developing extended-release pain medications

Compensation Overview

$240k - $260k/yr

Atlanta, GA, USA

In Person

Category
Biology & Biotech (1)
Required Skills
Veeva
Requirements
  • Advanced degree required: PhD, PharmD, MD, or equivalent doctoral-level degree in a scientific or healthcare-related discipline.
  • 8+ years of experience in Medical Affairs or related scientific roles within biopharmaceuticals, including prior MSL experience.
  • Demonstrated people-management experience, preferably leading or mentoring field-based medical teams.
  • Strong grounding in central nervous system disorders; ADHD experience highly preferred.
  • Experience operating effectively in small- to mid-sized organizations or high-growth environments is strongly preferred.
  • Proven ability to lead, coach, and develop high-performing scientific teams.
  • Strong scientific acumen with ability to translate complex clinical data into clear, balanced insights.
  • Excellent communication, collaboration, and stakeholder management skills.
  • High attention to compliance, documentation, and operational rigor.
  • Ability to travel regionally and nationally as required.
  • Field-based role with approximately 50–70% travel, including regional field travel and national meetings.
Responsibilities
  • Lead, coach, and develop a team of 6–7 Medical Science Liaisons to ensure high scientific standards, consistent execution, and professional growth across the region.
  • Translate national Medical Affairs objectives into clear regional plans, priorities, and expectations aligned with company strategy.
  • Foster a culture of scientific excellence, accountability, collaboration, and compliance across the MSL team.
  • Provide ongoing coaching, performance feedback, and development planning for direct reports.
  • Mentor MSLs in effective scientific exchange, clinical literature appraisal, insight generation, and compliant field engagement practices.
  • Partner with Medical Affairs leadership and HR on hiring, onboarding, and retention of high-performing MSL talent.
  • Oversee regional KOL engagement strategy, ensuring thoughtful identification, profiling, tiering, and long-term relationship development with ADHD and broader CNS experts.
  • Ensure appropriate balance of proactive and reactive scientific engagements, with attention to not overburdening key external experts.
  • Periodically engage directly with select KOLs and institutions to remain scientifically current and model best practices in peer-to-peer exchange.
  • Act as a regional Medical Affairs point of contact for Commercial, Market Access, Compliance, and other internal stakeholders, ensuring appropriate and compliant collaboration.
  • Provide scientific input and guidance to cross-functional partners regarding the ADHD treatment landscape, emerging data, and external expert perspectives.
  • Support regional and national medical initiatives including advisory boards, medical education programs, and scientific congress activities.
  • Ensure timely, accurate capture of scientific insights, medical inquiries, and field activities in approved systems (e.g., CRM/Veeva).
  • Synthesize regional trends and insights to inform Medical Affairs strategy, evidence generation, and lifecycle planning.
  • Support development and refinement of Medical Affairs processes, standard operating procedures (SOPs), and field best practices in partnership with Medical leadership and Compliance.
  • Ensure all regional medical activities adhere to company policies, SOPs, and applicable regulatory and compliance requirements.
  • Serve as a role model for ethical scientific exchange and appropriate field engagement in a non-promotional, patient-focused manner.
Collegium Pharmaceutical

Collegium Pharmaceutical

View

Preparing summary...

Company Size

501-1,000

Company Stage

IPO

Headquarters

Cumberland, Maryland

Founded

2002

Simplify Jobs

Simplify's Take

What believers are saying

  • Jornay PM Q1 2026 revenue hit $38.9 million, up 36% year-over-year.
  • AZSTARYS acquisition closes Q2 2026, projecting $50 million H2 2026 revenue.
  • 30,000 Jornay prescribers drive $190-200 million full-year 2026 guidance.

What critics are saying

  • Nucynta ER loses all revenue to generics mid-2026, slashing pain sales.
  • Adhansia XR erodes 20% of Jornay 2026 revenue via afternoon coverage.
  • Vyvanse caps Jornay growth at $150 million with 40% market dominance.

What makes Collegium Pharmaceutical unique

  • Jornay PM offers evening-dosed methylphenidate for ADHD morning symptom control.
  • AZSTARYS combines serdexmethylphenidate prodrug with dexmethylphenidate for dual-release.
  • Portfolio features tamper-resistant extended-release for pain and ADHD.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Collegium Pharmaceutical who can refer or advise you

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

-9%

1 year growth

-12%

2 year growth

-7%
Yahoo Finance
Mar 26th, 2026
Collegium Pharmaceutical shares drop 26.8% as Q4 guidance disappoints despite $205.4M revenue

Collegium Pharmaceutical reported Q4 revenues of $205.4 million, up 12.9% year-on-year, meeting analysts' expectations. However, the quarter delivered mixed results, with full-year revenue guidance beating expectations but earnings per share significantly missing estimates. The branded pharmaceuticals sector faces tailwinds from precision medicine advancements and AI adoption in drug development, but confronts challenges including regulatory scrutiny, pricing pressures and patent cliffs forcing competition from generics. CEO Vikram Karnani highlighted progress on strategic priorities, including growth for Jornay PM and maximising the pain portfolio. However, Collegium delivered the weakest full-year guidance amongst its peers. Shares have fallen 26.8% since the earnings report and currently trade at $33.51. The 10 branded pharmaceuticals stocks tracked reported mixed Q4 results, with revenues missing consensus estimates by 1.6% on average.

Yahoo Finance
Mar 25th, 2026
Collegium Pharmaceutical executive sells 50,000 shares worth $2M under pre-set plan

Scott Dreyer, Executive Vice President and Chief Commercial Officer of Collegium Pharmaceutical, sold 49,976 shares of common stock in open-market transactions on 3 March 2026, worth $2 million, according to an SEC Form 4 filing. The sale was executed under a Rule 10b5-1 trading plan established in September 2025, which allows executives to sell shares at predetermined times to avoid trading on inside information. The transaction represents 41% of Dreyer's direct holdings, substantially larger than his historical median sale of 15,387 shares. Following the transaction, Dreyer retains 71,770 shares held directly, valued at approximately $2.4 million. Collegium Pharmaceutical develops specialty pain management products including Xtampza ER and Nucynta ER/IR, with a market capitalisation of $1.1 billion.

Collegium Pharmaceutical
Mar 20th, 2026
Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory – Collegium Pharmaceutical Inc.

The Investor Relations website contains information about Collegium Pharmaceutical Inc.'s business for stockholders, potential investors, and financial analysts.

AllSci
Mar 19th, 2026
Collegium acquires ADHD drug Azstarys from Corium Therapeutics for USD 650m plus milestones.

Collegium acquires ADHD drug Azstarys from Corium Therapeutics for USD 650m plus milestones. March 19, 2026 Collegium Pharmaceutical, based in Stoughton, Massachusetts, announced a definitive agreement to acquire Azstarys from Corium Therapeutics Holdings for USD 650 million in cash at closing, with up to USD 135 million in additional milestone payments tied to commercial and regulatory targets. The Collegium Azstarys acquisition covers a marketed central nervous system stimulant indicated for attention deficit hyperactivity disorder in patients aged six and older. Corium Therapeutics, a privately held company headquartered in Cambridge, Massachusetts, markets and distributes the product through its subsidiaries. The transaction is expected to close in Q2 2026, subject to Hart-Scott-Rodino approval and other customary conditions (source). Azstarys is a fixed-dose combination capsule containing serdexmethylphenidate and dexmethylphenidate, representing a differentiated ADHD treatment combining both immediate-release and long-acting components. Serdexmethylphenidate is a prodrug of dexmethylphenidate. The dexmethylphenidate component provides the immediate-release onset, while the prodrug undergoes enzymatic conversion to deliver extended exposure. Both components act on dopamine and norepinephrine reuptake in the central nervous system. The product generated more than 760,000 prescriptions in 2025 and is expected to produce over USD 50 million in second-half 2026 pro forma net revenue. Six Orange Book-listed patents support the product, most of which do not expire until December 2037. Collegium will fund the upfront payment through existing cash on hand and USD 300 million from a delayed draw term loan that is part of a syndicated credit facility announced in December 2025. The term loan carries interest at the term Secured Overnight Financing Rate plus a spread of 2.75% to 3.75%, depending on the company's first lien net leverage ratio. At closing, the rate will be SOFR plus 3.25%. Collegium expects post-close net leverage of approximately two times estimated 2026 combined adjusted EBITDA. The company stated the transaction is expected to be immediately accretive to adjusted EBITDA. Annual run-rate synergies are projected to exceed USD 50 million within twelve months of closing. The Collegium ADHD portfolio already includes Jornay PM, a delayed-release and extended-release methylphenidate capsule designed for evening dosing. Adding Azstarys gives Collegium a second commercialized ADHD product with a different release profile and dosing schedule. Collegium has historically operated in responsible pain management and has been expanding into neuropsychiatry. The Azstarys Corium deal extends the patent-protected revenue horizon of the combined ADHD portfolio to 2037. The ADHD stimulant market includes multiple methylphenidate and amphetamine-based products across immediate-release, extended-release, and prodrug formulations. Competitors targeting the same pharmacological class include: - Vyvanse (lisdexamfetamine) - Takeda - approved, amphetamine prodrug - Concerta (methylphenidate ER) - Janssen - approved, osmotic-release formulation - Adhansia XR (methylphenidate ER) - Adamas Pharmaceuticals - approved, multilayer extended-release Your email address will not be published. Required fields are marked *

Endpoints News
Mar 19th, 2026
Collegium is acquiring Corium's approved ADHD drug for $650M.

Collegium is acquiring Corium's approved ADHD drug for $650M. Biotech correspondent. Collegium Pharmaceutical is beefing up its portfolio in ADHD with the acquisition of Corium's FDA-approved drug Azstarys. The $650 million upfront deal carries up to... Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.